Ecnoglutide (XW003) is a

GLP-1 agonist Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of ...

being developed for the treatment of obesity and

type 2 diabetes Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent ...

. In preclinical trials, "Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process" compared to other GLP-1 agonists. A phase 3 trial published in 2025 showed double-digit weightloss over a 48 week treatment.

References

GLP-1 receptor agonists Experimental diabetes drugs {{Med-stub